Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

594 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Established gastric cancer cell lines transplantable into C57BL/6 mice show fibroblast growth factor receptor 4 promotion of tumor growth.
Yamamoto M, Nomura S, Hosoi A, Nagaoka K, Iino T, Yasuda T, Saito T, Matsushita H, Uchida E, Seto Y, Goldenring JR, Kakimi K, Tatematsu M, Tsukamoto T. Yamamoto M, et al. Among authors: nagaoka k. Cancer Sci. 2018 May;109(5):1480-1492. doi: 10.1111/cas.13569. Epub 2018 Apr 15. Cancer Sci. 2018. PMID: 29532565 Free PMC article.
Different immunological effects of the molecular targeted agents sunitinib, everolimus and temsirolimus in patients with renal cell carcinoma.
Kobayashi Y, Yamada D, Kawai T, Sato Y, Teshima T, Yamada Y, Nakamura M, Suzuki M, Matsumoto A, Nakagawa T, Hosoi A, Nagaoka K, Karasaki T, Matsushita H, Kume H, Kakimi K. Kobayashi Y, et al. Among authors: nagaoka k. Int J Oncol. 2020 Apr;56(4):999-1013. doi: 10.3892/ijo.2020.4975. Epub 2020 Feb 4. Int J Oncol. 2020. PMID: 32319571
Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study.
Kakimi K, Matsushita H, Masuzawa K, Karasaki T, Kobayashi Y, Nagaoka K, Hosoi A, Ikemura S, Kitano K, Kawada I, Manabe T, Takehara T, Ebisudani T, Nagayama K, Nakamura Y, Suzuki R, Yasuda H, Sato M, Soejima K, Nakajima J. Kakimi K, et al. Among authors: nagaoka k. J Immunother Cancer. 2020 Sep;8(2):e001185. doi: 10.1136/jitc-2020-001185. J Immunother Cancer. 2020. PMID: 32948652 Free PMC article. Clinical Trial.
Deep immunophenotyping at the single-cell level identifies a combination of anti-IL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized immunotherapy.
Nagaoka K, Shirai M, Taniguchi K, Hosoi A, Sun C, Kobayashi Y, Maejima K, Fujita M, Nakagawa H, Nomura S, Kakimi K. Nagaoka K, et al. J Immunother Cancer. 2020 Oct;8(2):e001358. doi: 10.1136/jitc-2020-001358. J Immunother Cancer. 2020. PMID: 33093158 Free PMC article.
Integrative immunogenomic analysis of gastric cancer dictates novel immunological classification and the functional status of tumor-infiltrating cells.
Sato Y, Wada I, Odaira K, Hosoi A, Kobayashi Y, Nagaoka K, Karasaki T, Matsushita H, Yagi K, Yamashita H, Fujita M, Watanabe S, Kamatani T, Miya F, Mineno J, Nakagawa H, Tsunoda T, Takahashi S, Seto Y, Kakimi K. Sato Y, et al. Among authors: nagaoka k. Clin Transl Immunology. 2020 Oct 17;9(10):e1194. doi: 10.1002/cti2.1194. eCollection 2020. Clin Transl Immunology. 2020. PMID: 33101677 Free PMC article.
Two distinct phenotypes of immunologically hot gastric cancer subtypes.
Saito N, Kobayashi Y, Nagaoka K, Kushihara Y, Sato Y, Wada I, Kakimi K, Seto Y. Saito N, et al. Among authors: nagaoka k. Biochem Biophys Rep. 2021 Nov 3;28:101167. doi: 10.1016/j.bbrep.2021.101167. eCollection 2021 Dec. Biochem Biophys Rep. 2021. PMID: 34786494 Free PMC article.
594 results